Please ensure Javascript is enabled for purposes of website accessibility

Here’s Why Lexicon Pharmaceuticals Rose 18% Today

By Brian Orelli, PhD – Sep 16, 2019 at 4:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are jumping in ahead of a data presentation tomorrow.

What happened

Shares of Lexicon Pharmaceuticals (LXRX -0.41%) were up 18% at 3:39 p.m. EDT on Monday in anticipation of the biotech presenting data on its diabetes drug Zynquista at the European Association for the Study of Diabetes (EASD) annual meeting tomorrow.

So what

Zynquista is an SGLT inhibitor designed to increase the removal of sugar from diabetic patients through their urine via the kidneys. It's a multibillion-dollar drug class in type 2 diabetes, but the class has had trouble breaking into type 1 diabetes.

The Food and Drug Administration turned down an application to approve the drug as a treatment for type 1 diabetes in March. But European regulators approved the drug -- and a competing one from AstraZeneca -- in overweight type 1 diabetics. Not surprisingly, reducing sugar in the bloodstream not only helps improve diabetes symptoms but can also help patients lose weigh.

Lexicon's two presentations at EASD on Tuesday will focus on the effects of Zynquista on body weight. The hope is that the data could help persuade regulators at the FDA to change their minds or, at the very least, help the European launch of Zynquista.

Hands using a glucose meter

Image source: Getty Images.

Now what

Lexicon will either need to launch Zynquista on its own or find a partner, because its former partner Sanofi (SNY 0.05%) recently backed out of their deal. Fortunately, Lexicon got $260 million in the breakup, so it has a bit of a cushion to get back on its feet.

The EASD presentations could be a good start. Just keep in mind: When investing in biotechs, data releases are often sell-the-news events, so buying at today's inflated price ahead of the data might not be the best short-term move.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
LXRX
$2.40 (-0.41%) $0.01
Sanofi Stock Quote
Sanofi
SNY
$38.02 (0.05%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.